Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. (Q53130253)
Jump to navigation
Jump to search
scientific article published on 5 December 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. |
scientific article published on 5 December 2012 |
Statements
Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. (English)
Luca Bologna
Elisa Gotti
Fabio Da Roit
Tamara Intermesoli
Alessandro Rambaldi
5 December 2012
190
1
231-239